Regentis Biomaterials expanded its European clinical sites to boost patient recruitment and trial efficiency.

Three Aura Biosciences insiders sold $425K in stock on Feb. 17, 2026, reducing their combined stake by 8%.

Hearing loss in older adults is linked to cognitive decline through shared brain connectivity issues, suggesting a potential dementia risk and a new biomarker.

Oxybutynin reduced hot flashes in prostate cancer patients on hormone therapy, improving sleep and quality of life with minimal side effects.

Mubadala Bio completes full acquisition of Al Ittihad Drug Store and Global Medical Supply Chain, boosting UAE’s healthcare resilience.

Aspire Biopharma files patent for fast-acting sublingual meclizine to treat motion sickness.

BioNxt gains EU patent for needle-free cladribine treatment, protecting it in 39 countries until 2043.

A new AI tool predicts colorectal cancer risk in ulcerative colitis patients with high accuracy, enabling safer colonoscopy scheduling.

MD Anderson researchers created TmS, a new biomarker that better predicts chemo response in triple-negative breast cancer by analyzing tumor gene activity and microenvironment, showing promise for personalized treatment.

Japan approves first human milk-based fortifiers as prescription drugs for premature infants.